

Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest  
and Waiver under 18 U.S.C. §208(b)(3)

Andrew Leon, Ph.D.

**Committee:** Psychopharmacologic Drugs Advisory Committee

**Meeting Date:** December 13, 2006

I acknowledge that contingent upon public disclosure of the financial interest listed below, related to the committee's discussions of the results of the FDA ongoing meta-analysis of suicidality data from adult antidepressant trials. I am eligible to receive a waiver under 18 U.S.C. §208 (b)(3).

<b>Type of Interest</b>	<b>Nature</b>	<b>Magnitude</b>
Member - Data Safety Monitoring Board	Affected Firm	Between \$10,001 to \$50,000 per year.

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of this interest the waiver is not valid.

\_\_\_\_\_/s/\_\_\_\_\_  
Signature of SGE

\_\_\_\_\_/11/6/06\_\_\_\_\_  
Date